Scholarlink

Background <p>Pathogenic variants in <i>GRIN2B</i> are predominantly associated with neurodevelopmental disorders (NDDs). However, our understanding of the genotype-phenotype correlations and the optimal treatment strategies is limited.</p> Methods <p>We collected clinical data of seven new patients from the Xiangya Hospital and conducted an extensive literature review. Subsequently, we carried out comparisons of clinical features between patients with gain-of-function (GOF) variants and patients with loss-of-function (LOF) variants, as well as patients with LOF missense variants and LOF truncating variants.</p> Results <p>We identified seven patients, five of whom had novel variants (p.Phe554Ser, p.Val821Phe, p.Ile641Thr, p.Asn649Ser, and p.Gly1182Arg), and two of whom had known variants (p.Gly820Val and p.Met818Leu). Of the seven cases, 4 (57.14%) presented with epilepsy. Two of these individuals (carrying the p.Ile641Thr and p.Met818Leu variants, respectively) achieved seizure control after receiving memantine. The clinical manifestations included severe developmental delay /intellectual disability (DD/ID) and hypotonia in 100% of cases, as well as microcephaly in 28.57% of cases. Brain imaging results were available for six cases, five of which (83.33%) had abnormal results. Combining our patients (<i>n</i> = 7) and those reported in the literature (<i>n</i> = 98), a total of 105 patients were analyzed. These patients carried 84 pathogenic variants, ten of which were recurrent. The two most frequently occurring variants were p.Gly820Ala and p.Gly689Ser. The predominant phenotypes observed were DD/ID (100%), hypotonia (87.27%), epilepsy (53.08%), and language impairment (45.71%). We further analyzed the clinical genotypes and phenotypes of 55 patients with LOF variants and 16 patients with GOF variants. Variants located in the transmembrane domain predominantly resulted in a GOF effect. GOF variants were more likely to cause epilepsy and microcephaly than LOF variants. Moreover, in comparison to LOF truncated variants, missense variants were associated with more severe clinical phenotypes, including severe DD/ID, language delay, and movement disorders.</p> Conclusions <p>This study reports five novel <i>GRIN2B</i> variants and seven additional patients. Notably, it is the first report to distinguish between GOF and LOF <i>GRIN2B</i> variants, which have distinct clinical phenotypes. Furthermore, memantine has been shown to be effective in controlling seizures and improving cognition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GRIN2B-related neurodevelopmental disorders: genotype-phenotype correlations and therapeutic implications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Changning Xie,
  • Miriam Kessi,
  • Fangyun Liu,
  • Fang He,
  • Jing Peng

摘要

Background

Pathogenic variants in GRIN2B are predominantly associated with neurodevelopmental disorders (NDDs). However, our understanding of the genotype-phenotype correlations and the optimal treatment strategies is limited.

Methods

We collected clinical data of seven new patients from the Xiangya Hospital and conducted an extensive literature review. Subsequently, we carried out comparisons of clinical features between patients with gain-of-function (GOF) variants and patients with loss-of-function (LOF) variants, as well as patients with LOF missense variants and LOF truncating variants.

Results

We identified seven patients, five of whom had novel variants (p.Phe554Ser, p.Val821Phe, p.Ile641Thr, p.Asn649Ser, and p.Gly1182Arg), and two of whom had known variants (p.Gly820Val and p.Met818Leu). Of the seven cases, 4 (57.14%) presented with epilepsy. Two of these individuals (carrying the p.Ile641Thr and p.Met818Leu variants, respectively) achieved seizure control after receiving memantine. The clinical manifestations included severe developmental delay /intellectual disability (DD/ID) and hypotonia in 100% of cases, as well as microcephaly in 28.57% of cases. Brain imaging results were available for six cases, five of which (83.33%) had abnormal results. Combining our patients (n = 7) and those reported in the literature (n = 98), a total of 105 patients were analyzed. These patients carried 84 pathogenic variants, ten of which were recurrent. The two most frequently occurring variants were p.Gly820Ala and p.Gly689Ser. The predominant phenotypes observed were DD/ID (100%), hypotonia (87.27%), epilepsy (53.08%), and language impairment (45.71%). We further analyzed the clinical genotypes and phenotypes of 55 patients with LOF variants and 16 patients with GOF variants. Variants located in the transmembrane domain predominantly resulted in a GOF effect. GOF variants were more likely to cause epilepsy and microcephaly than LOF variants. Moreover, in comparison to LOF truncated variants, missense variants were associated with more severe clinical phenotypes, including severe DD/ID, language delay, and movement disorders.

Conclusions

This study reports five novel GRIN2B variants and seven additional patients. Notably, it is the first report to distinguish between GOF and LOF GRIN2B variants, which have distinct clinical phenotypes. Furthermore, memantine has been shown to be effective in controlling seizures and improving cognition.